Assembly biosciences provides update on the ongoing phase 2 extension study of vebicorvir in patients with chronic hepatitis b virus infection

- hbv field's first c ore i nhibitor combination study to assess off-treatment response has not achieve d a meaningful rate of sustained virologic response -  - vebicorvir phase 3 registrational program remain s on track to i nitiate in h1 2021 for c hronic s uppressive t herapy - - assembly bio to host conference call today at 5:00 p . m . et -
ASMB Ratings Summary
ASMB Quant Ranking